Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Sitagliptin Phosphate Tablet Formulations in Healthy Thai Volunteers (Fasting)
TCTR20200108002Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novartis. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start May 2020; status: not yet recruiting.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20200108002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200108002.